Amgen Inc.'s common stock kept rising Friday as investorscontinued to react to the Food and Drug Administration'smarketing approval of Amgen's granulocyte colony stimulatingfactor (G-CSF). The stock (NASDAQ:AMGN) rose almost $10before falling back to close at $101.75, up $6.25 overThursday's closing price. Immunex Corp. stock (NASDAQ:IMNX)also rose, closing up $5 at $45.50. Immunex expects itscompeting drug, granulocyte macrophage colony stimulatingfactor (GM-CSF), to be approved "within days or weeks."
(c) 1997 American Health Consultants. All rights reserved.